Etodolac
Indole acetic acid derivative
También conocido como: EtoGesic · Lodine · AY-24236 · etodolacum · etodolic acid · Acudor · Articulan · Dualgan · Eccoxolac · Edolan · Elderin · Etonox · Etopan · Flancox · Hypen · Lodot · Lonine · Metazin · Sodolac · Ultradol · Zedolac
Revisado por el equipo veterinario de VetSheetActualizado 5 abr 2026Referencia veterinaria basada en la evidencia
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Dosis por especie
🌎 NA — North America🌍 EU — Europe
Perros
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Treatment of pain and inflammation associated with osteoarthritis | 10-15 mg/kg | PO | once daily | — | 🌎 NA |
| Treatment of pain and inflammation associated with osteoarthritis | 10-15 mg/kg | SC | once | — | 🌎 NA |
- Treatment of pain and inflammation associated with osteoarthritis: Dogs less than 5 kg cannot be accurately dosed with EtoGesic tablets. Adjust dose to obtain satisfactory response, but do not exceed 15 mg/kg. For long-term therapy, reduce dose level to minimum effective dosage.
- Treatment of pain and inflammation associated with osteoarthritis: Administer as a dorsoscapular subcutaneous injection. If needed, daily doses of tablets may begin 24 hours after the last injectable treatment. Use alternate injection sites.
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Resumen
Etodolac es un fármaco antiinflamatorio no esteroideo (AINE) utilizado principalmente en medicina veterinaria para el control del dolor y la inflamación asociados con la osteoartritis en perros.
- Disponible tanto en formulaciones de tabletas orales como inyectables.
- Se caracteriza por una vida media relativamente larga en perros, lo que permite una cómoda dosificación una vez al día.
- Perla clínica: Aunque es eficaz, el etodolac tiene un índice terapéutico más estrecho en comparación con algunos AINE veterinarios más nuevos (p. ej., carprofen, meloxicam), lo que significa que la dosificación precisa es fundamental para evitar la toxicidad gastrointestinal. Dosis tan bajas como 2.7X la dosis terapéutica pueden producir lesiones gastrointestinales.
Mecanismo de acción
Etodolac exerts its analgesic, anti-inflammatory, and antipyretic effects primarily by inhibiting the cyclooxygenase (COX) enzymes.
- Arachidonic Acid → Prostaglandins: By blocking COX, etodolac prevents the conversion of arachidonic acid into pro-inflammatory prostaglandins.
- It is generally considered a COX-1 sparing drug rather than highly COX-2 selective in dogs. In horses, it does not exhibit much COX-2 selectivity.
- Additionally, etodolac inhibits macrophage chemotaxis, which further blunts the inflammatory cascade at the site of tissue injury.
Seguridad y advertencias
Contraindicaciones
- Known hypersensitivity to etodolac
- Dogs less than 12 months of age
- Breeding, pregnant, or lactating dogs (safe use not established)
- Cats (highly sensitive to toxicity)
Efectos adversos
- Vomiting
- Regurgitation
- Diarrhea
- Lethargy
- Hypoproteinemia
- Urticaria
- Behavioral changes
- Inappetence
- Hepatotoxicity (rare)
- Nephrotoxicity (rare)
- Localized pain or tissue reactions at injection site
- Decreased total serum T4
- Keratoconjunctivitis sicca (KCS)
Precauciones
Use with caution in dogs with preexisting or occult GI, hepatic, renal, cardiovascular, or hematologic abnormalities as NSAIDs may exacerbate these conditions.
Important: Patients may be more susceptible to renal injury from etodolac if they are dehydrated, on diuretics, or have preexisting renal, hepatic, or cardiovascular dysfunction.
Terminate therapy if inappetence, vomiting, fecal abnormalities, or anemia are observed.
Interacciones farmacológicas
May reduce antihypertensive effects and increase the risk for renal injury.
May decrease etodolac plasma levels and increase likelihood of GI adverse effects (blood loss). Concomitant use is not recommended.
May increase cyclosporine blood levels and increase the risk for nephrotoxicity.
May increase serum levels of digoxin. Use with caution in severe cardiac failure.
May reduce the saluretic and diuretic effects of furosemide.
Serious toxicity has occurred with concomitant NSAID use.
Potential for increased risk of nephrotoxicity.
May increase the metabolism of etodolac in dogs.
May cause a significant increase in serum levels and half-life of etodolac.
May increase the risk for bleeding.
Monitorización
- Baseline physical exam, CBC, Serum chemistry panel (liver and renal function), and Urinalysis
- Reassess liver enzymes at one week of therapy
- Tear production (Schirmer Tear Test) prior to and during therapy due to KCS risk
- Clinical efficacy (pain scoring)
- Signs of adverse reactions: inappetence, vomiting, melena, diarrhea, PU/PD, jaundice, lethargy
Farmacocinética
Vida media
Absorción
Rapidly and nearly completely absorbed after oral administration. Food may alter the rate, but not the extent, of absorption. Peak serum levels occur about 2 hours post dosing. Oral bioavailability in horses is about 77%.
Distribución
Highly bound to serum proteins. In horses, volume of distribution is 0.29 L/kg.
Metabolismo
Glucuronide conjugates have been detected in the bile but not the urine.
Eliminación
Primarily excreted via the bile into the feces. Rate of enterohepatic circulation may be affected by the presence of food in the gut.
Sobredosis
Etodolac has a relatively narrow therapeutic window in dogs.
- 2.7X overdose (40 mg/kg/day): Can cause GI ulcers, weight loss, emesis, and local occult blood.
- 5.3X overdose (80 mg/kg/day): Highly lethal; caused death or moribund state secondary to severe GI ulceration in safety studies.
- Feline Toxicity: Cats are highly sensitive. Exposures have resulted in acute renal failure, anorexia, collapse, hyperkalemia, and hypersalivation.
Treatment: Decontamination with emetics and/or activated charcoal may be appropriate for acute ingestions. Use gastrointestinal protectants for expected GI effects. If renal effects are anticipated, aggressive fluid diuresis is warranted.
Productos disponibles
Formulaciones
- Oral tablets
- Subcutaneous injection
Veterinario
- Etodolac Scored Tablets: 150 mg & 300 mg (EtoGesic)
- Etodolac Injection 10% (100 mg/mL) in 50 mL vials (EtoGesic Injectable)
Etiquetado para humanos
- Etodolac Tablets: 400 mg & 500 mg
- Etodolac Capsules: 200 mg & 300 mg
- Etodolac Extended-release tablets: 400 mg, 500 mg & 600 mg
Estado regulador
Sin datos reguladores para: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Almacenamiento y estabilidad
Veterinary tablets should be stored at controlled room temperature (15-30°C). Injection should be stored at or below 77°F (25°C).
Información para el cliente
Administración: Administre el medicamento exactamente como lo recetó su veterinario. A menudo es mejor administrarlo con comida para reducir la posibilidad de malestar estomacal.
Esté atento a los efectos secundarios: Suspenda el medicamento inmediatamente y comuníquese con su veterinario si su perro experimenta:
- Vómitos o regurgitación
- Diarrea o heces oscuras y alquitranadas (melena)
- Pérdida de apetito o letargo extremo
- Aumento de la sed o la micción
Salud ocular: En raras ocasiones, este medicamento puede causar "ojo seco" (queratoconjuntivitis seca). Esté atento a un parpadeo excesivo, enrojecimiento o secreción ocular espesa y pegajosa.
ADVERTENCIA: Nunca administre este medicamento a gatos u otras mascotas, ya que puede ser altamente tóxico y potencialmente fatal para ellos. Manténgalo fuera del alcance de todos los animales y niños.
La referencia de medicamentos de VetSheet está destinada a profesionales veterinarios autorizados como ayuda para la toma de decisiones clínicas, no como sustituto del criterio profesional ni del prospecto actual del fabricante.